A new indoor skatepark has opened in Cornwall. TR7 Skatepark near Roche is 370 sq m (4,000 sq ft) and features a mini-ramp, rails, ledges and hips. It also has an open area for beginners and a ...

Our weekend morning emails feature the very best news and exclusive content from our team of reporters An 'adored' ...

Near St Austell in Cornwall, the medieval chapel of St Michael at Roche Rock sits on a tall outcrop of granite rising up in ...

An "amazing" new type of mineral has been discovered by scientists analysing a rock mined in Cornwall about 220 years ago. The dark green mineral has been named kernowite after Kernow, the Cornish ...

Roche ROG-1.53%decrease; red down pointing triangle confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and hemophilia injection Hemlibra ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single patient was enrolled. The withdrawal, which ApexOnco reported earlier ...

Roche’s new TAGS technology overcomes the technical limitations of a typical 4-plex test result in previous solutions, using a novel, proprietary approach. Without having to upgrade hardware or ...

Roche doesn’t think so. “I think we don’t see anything that should be slowing Vabysmo momentum down,” Teresa Graham, CEO of Roche Pharmaceuticals, said during a press conference Wednesday ...

FRANKFURT, Oct 23 (Reuters) - The CEO of Roche (ROG.S), opens new tab said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the ...

Swiss Pharmaceutical giant Roche Holding (OTCQX:RHHBY) (OTCQX:RHHBF) on Wednesday reaffirmed its full-year sales and earnings outlook after the company’s third-quarter sales results exceeded ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.